Ruxolitinib (Opzelura) for Atopic Dermatitis
Date: January 24, 2022 Issue #:  1642Summary:  The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura– Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients≥12 years old whose disease has not been adequately controlled with other topical prescription drugs. Ruxolitinib is the first JAK inhibitor to be approved for topical use and the first to be approved in the US for treatment of AD. An oral formulation of ruxolitinib(Jakafi) is approved for...
Source: The Medical Letter - December 10, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Atopic dermatitis corticosteroids crisaborole Elidel Eucrisa Jakafi Jakavi Opzelura Pimecrolimus Protopic ruxolitinib Tacrolimus tofacitinib Xeljanz Source Type: research

Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial
CONCLUSION: This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus.PMID:34887918 | PMC:PMC8651420 | DOI:10.1155/2021/5652140 (Source: Dermatology Research and Practice)
Source: Dermatology Research and Practice - December 10, 2021 Category: Dermatology Authors: Fariba Iraji Ali Asilian Zahra Talebzadeh Mina Saber Fatemeh Mokhtari Amirhossein Siadat Seyed Mohsen Hosseini Source Type: research